Danelle Johnston, MSN, RN, HON-ONN-CG, OCN, and Tricia Strusowski, RN, MS, recapped their recent presentation from the ACCC 46th Annual Meeting & Cancer Center Business Summit, in which they discussed the National Evidence-Based Oncology Navigation Metrics: Multisite Exploratory Study to Demonstrate Value and Sustainability of Navigation Programs. The study was launched in June 2018 as a collaborative effort between the Academy of Oncology Nurse & Patient Navigators (AONN+), Chartis Oncology Solutions, and the American Cancer Society (ACS).
Nurses and navigators play a crucial role in teaching patients about genetics and genomics, as well as in gathering the vital information necessary to actually carry out genetic testing and allowing patients to take control of their genetic inheritance.
At the 2018 AONN+ Annual Conference, attendees heard a rapid-fire rundown of some of the most newsworthy, and sometimes controversial, topics in cancer care.
Patients with cancer, even in the most “favorable” of circumstances, often face hurdles to care.
Whether an oncology navigation program is just starting out or has already become a well-oiled machine, there are usually a few—or perhaps, quite a few—ways that a navigation program can potentially be improved, according to Lillie D. Shockney, RN, BS, MAS, ONN-CG, Co-Founder and Program Director of the Academy of Oncology Nurse & Patient Navigators (AONN+).
The PD-L1 inhibitor durvalumab showed an overall survival benefit in patients with unresectable stage III non–small cell lung cancer (NSCLC) in the phase 3 PACIFIC trial.
Researchers are chipping away at the genetic subtypes of non–small-cell lung cancer (NSCLC).
Entrectinib achieved high response rates as well as durable responses in patients with ROS1-positive non–small cell lung cancer (NSCLC), including patients with brain metastases, according to a pooled analysis of phase 1 and 2 trials.
Atezolizumab combined with carboplatin/etoposide represents a new standard of care for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), according to results from the phase 3 IMpower133 trial presented at the IASLC 19th World Conference on Lung Cancer.
Brigatinib significantly prolonged survival compared with crizotinib (standard of care) as first-line therapy in patients with advanced anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC).